AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
Status:
Terminated
Trial end date:
2018-10-29
Target enrollment:
Participant gender:
Summary
This study is a single arm, multi-center phase II study of AZD 2811 monotherapy in patients
with relapsed small cell lung cancer (SCLC) as a second or third line therapy.
Patients will continue to receive study treatment as described above, until they demonstrate
objective disease progression (determined by RECIST 1.1) or they meet any other
discontinuation criteria.